Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid a…
Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings in EuropeThe annual, international research undertaken by the Top Employers Institute recognizes leading employers around the worldThis exclusiv…
Japanese generic market set to expand rapidly, driven by government commitment to achieving sustainable high-quality healthcareSandoz Japan plans 70 new launches over next six years, which will accountfor ~40% of total sales by 2022Growth drivers will …
FY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance Cosentyx (USD 1.1 billion) reached blockbuster statusEntresto (USD 170 million) continued to grow steadily, following positive treatment guidelines in US and Euro…
ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1]Interim data in over 600 adults show potential of GP2013 as an alternative ritux…
Princeton, New Jersey, November 22, 2016. Sandoz today announced a collaboration to increase access to medicines by donating up to USD 10 million of stock annually to Americares, a health-focused relief and development organization that responds to peo…
No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1]Innovative study design demonstrates switching between biosimilar etanercept and the originator product has no impact o…
Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growthCosentyx (USD 301 million) on track for blockbuster status in first full year …
Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical needSandoz “HACk” – Healthcare Access Challenge – is a competition seeking young people with innovative ideas to “re…
Sandoz, a Novartis division, the pioneer and global leader in biosimilars acquired the rights from Pfizer for the development, commercialization and manufacture of PF-06438179 in the 28 countries that form the European Economic Area (EEA)* in February …